These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 18311451)

  • 1. Palmoplantar pustular psoriasis: successful therapy with efalizumab after non-response to infliximab.
    Wozel G; Vitez L
    Acta Derm Venereol; 2008; 88(2):169-70. PubMed ID: 18311451
    [No Abstract]   [Full Text] [Related]  

  • 2. Palmoplantar pustular psoriasis: successful therapy with efalizumab after non-response to infliximab.
    Wozel G; Vitéz L; Meurer M
    Acta Dermatovenerol Alp Pannonica Adriat; 2008 Sep; 17(3):133-6. PubMed ID: 18853077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of efalizumab in psoriasis patients previously treated with tumour necrosis factor blockers.
    Costanzo A; Talamonti M; Botti E; Spallone G; Papoutsaki M; Chimenti S
    Dermatology; 2009; 219(1):48-53. PubMed ID: 19372639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infliximab then efalizumab, the 'hit and run' approach does not work.
    Barde C; Thielen AM; Saurat JH
    Dermatology; 2008; 216(2):171-2. PubMed ID: 18216482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid response to infliximab in severe pustular psoriasis, von Zumbusch type.
    Newland MR; Weinstein A; Kerdel F
    Int J Dermatol; 2002 Jul; 41(7):449-52. PubMed ID: 12121565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of recalcitrant pustular psoriasis with infliximab: effective reduction of chemokine expression.
    Benoit S; Toksoy A; Bröcker EB; Gillitzer R; Goebeler M
    Br J Dermatol; 2004 May; 150(5):1009-12. PubMed ID: 15149518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response of severe psoriasis to infliximab.
    Mang R; Stege H; Ruzicka T; Krutmann J
    Dermatology; 2002; 204(2):156-7. PubMed ID: 11937748
    [No Abstract]   [Full Text] [Related]  

  • 8. Infliximab- and methotrexate-resistant rebound of psoriasis after discontinuation of efalizumab (Raptiva).
    Thielen AM; Barde C; Saurat JH
    Br J Dermatol; 2006 Oct; 155(4):846-7. PubMed ID: 16965444
    [No Abstract]   [Full Text] [Related]  

  • 9. Successful treatment of hand and foot psoriasis with efalizumab therapy.
    Fretzin S; Crowley J; Jones L; Young M; Sobell J
    J Drugs Dermatol; 2006 Oct; 5(9):838-46. PubMed ID: 17039648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term management of generalized pustular psoriasis with infliximab: case series.
    Routhouska SB; Sheth PB; Korman NJ
    J Cutan Med Surg; 2008; 12(4):184-8. PubMed ID: 18627699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions.
    Oh CJ; Das KM; Gottlieb AB
    J Am Acad Dermatol; 2000 May; 42(5 Pt 1):829-30. PubMed ID: 10775863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different response rates between palmoplantar involvement and diffuse plaque psoriasis in patients treated with infliximab.
    Brunasso AM; Puntoni M; Delfino C; Massone C
    Eur J Dermatol; 2012; 22(1):133-5. PubMed ID: 22134100
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of palmoplantar psoriasis with infliximab: a randomized, double-blind placebo-controlled study.
    Bissonnette R; Poulin Y; Guenther L; Lynde CW; Bolduc C; Nigen S
    J Eur Acad Dermatol Venereol; 2011 Dec; 25(12):1402-8. PubMed ID: 21349113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Life-threatening pustular and erythrodermic psoriasis responding to infliximab.
    Lewis TG; Tuchinda C; Lim HW; Wong HK
    J Drugs Dermatol; 2006 Jun; 5(6):546-8. PubMed ID: 16774108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor necrosis factor (TNF) inhibitors revolutionalized therapy for both psoriasis and psoriatic arthritis. Foreword.
    Gottlieb AB
    Am J Clin Dermatol; 2014 Feb; 15 Suppl 1():S3-4. PubMed ID: 24777570
    [No Abstract]   [Full Text] [Related]  

  • 16. Recalcitrant, generalized pustular psoriasis: rapid and lasting therapeutic response to antitumour necrosis factor-alpha antibody (infliximab).
    Schmick K; Grabbe J
    Br J Dermatol; 2004 Feb; 150(2):367. PubMed ID: 14996114
    [No Abstract]   [Full Text] [Related]  

  • 17. Successful treatment of Von Zumbusch pustular psoriasis with infliximab.
    Trent JT; Kerdel FA
    J Cutan Med Surg; 2004; 8(4):224-8. PubMed ID: 16091999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infliximab monotherapy in psoriasis: a case of rapid clinical and histological response.
    Vincek V; Jacob SE; Nassiri M; Herbert LM; Nadji M; Kerdel FA
    Int J Dermatol; 2004 Apr; 43(4):303-8. PubMed ID: 15090021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infliximab for psoriasis.
    Gottlieb AB
    J Am Acad Dermatol; 2003 Aug; 49(2 Suppl):S112-7. PubMed ID: 12894134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful treatment of recalcitrant palmoplantar pustular psoriasis with sequential use of infliximab and adalimumab.
    Yawalkar N; Hunger RE
    Dermatology; 2009; 218(1):79-83. PubMed ID: 18974629
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.